Prima BioMed Ltd. announced that it has entered into new collaboration agreement with Cytlimic to test cancer peptide vaccine in combination with IMP321. Under the material transfer agreement, the company will provide IMP321 for a formulation development targeting a new pre-clinical and clinical development study to be conducted by Cytlimic. When IMP321 is used as an adjuvant to a cancer vaccine to boost tumor-specific CD8 T cells, it is used at a very low dose to get a local effect at the vaccine injection site. The use of IMP321 as an adjuvant to a vaccine is therefore different from Prima's other combination approaches where higher doses are used to boost Antigen Presenting Cells in the whole body.